

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A substance for ~~preventing, delaying the onset of or treating~~ inhibiting the development of type I diabetes, the substance comprising a polynucleotide construct comprising a polynucleotide sequence encoding the pro-apoptotic protein BAX operatively linked to a CMV promoter and encoding secreted glutamic acid decarboxylase (secreted GAD~~55~~).

2. (currently amended) A method of making a medicament ~~comprising a polynucleotide construct comprising a polynucleotide sequence encoding the pro-apoptotic protein BAX and encoding secreted glutamic acid decarboxylase (secreted GAD) for the manufacture of a medicament for preventing, delaying the onset of or treating~~ inhibiting the development of type I diabetes, the method comprising providing a polynucleotide construct comprising a polynucleotide sequence encoding the pro-apoptotic protein BAX operatively linked to a CMV promoter and encoding secreted glutamic acid decarboxylase (secreted GAD~~55~~).

3. (canceled)

4. (canceled)

5. (previously presented) The method according to claim 2, where the medicament is manufactured in dosage units of between about 0.5 mg to about 5 mg.

6. (previously presented) The method according to claim 2, where the medicament is manufactured in dosage units of between about 1 mg to about 4 mg.

7. (previously presented) The method according to claim 2, where the medicament is manufactured in dosage units of between about 2.5 mg to about 3 mg.

8-9. (canceled)

10. (currently amended) A method for ~~preventing, delaying the onset of or treating~~ inhibiting the development of type I diabetes in a patient comprising:

a) selecting a patient who is susceptible to developing type I diabetes, who is developing type I diabetes or who has type I diabetes; and

b) administering to the patient intramuscularly one or more than one dose of a polynucleotide construct comprising a polynucleotide sequence encoding the pro-apoptotic protein BAX operatively linked to a CMV promoter and encoding secreted glutamic acid decarboxylase (secreted GAD55).

11. (canceled)

12. (previously presented) The method of claim 10, where selecting the patient comprises identifying in the patient the presence of anti-insulin or anti-GAD autoantibodies or both anti-insulin and anti-GAD autoantibodies.

13. (previously presented) The method of claim 10, where selecting the patient comprises identifying in the patient the presence of increasing hyperglycemia.

14. (previously presented) The method of claim 10, where selecting the patient comprises identifying in the patient the presence of glycosuria.

15. (previously presented) The method of claim 10, where selecting the patient comprises identifying in the patient the presence of a genetic predisposition type I diabetes.

16. (original) The method of claim 10, where the one or more than one dose is a plurality of doses.

17. (canceled)

18. (previously presented) The method of claim 10, further comprising, after administering, monitoring the patient for the development type I diabetes.

19-24. (canceled)